Last reviewed · How we verify
NCT05499949: FONS
The Franciscus Obesity NASH Study
trial testing NASH screening in NAFLD in 300 participants. Participants enrolled and being followed up; not accepting new ones.
1 September 2023
Quick facts
| Lead sponsor | Franciscus Gasthuis |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 September 2022 |
| Primary completion | 1 September 2023 |
| Estimated completion | 1 September 2029 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- NASH screening
- Cardiac dysfunction screening
- Liver biopsy — full drug profile →
Conditions studied
- NAFLD — all drugs for NAFLD →
- NASH - Nonalcoholic Steatohepatitis — all drugs for NASH - Nonalcoholic Steatohepatitis →
- Obesity, Morbid — all drugs for Obesity, Morbid →
Sponsor
Franciscus Gasthuis — full company profile →
Who can join
Adults 18 to 65, any sex, with NAFLD or NASH - Nonalcoholic Steatohepatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) changes in terms of steatosis and elasticity in patients with morbid obesity 1, 3 and 5 years after bariatric surgery. In addition, genomics, microbiome and metabolomics analyses will be carried out.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study.
Theel WB, Boxma-de Klerk BM, Dirksmeier-Harinck F, van Rossum EF, et al · · 2023 · cited 3× · PMID 37400234 · DOI 10.1136/bmjopen-2022-070431
Verify or expand the search:
- PubMed search for NCT05499949
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NAFLD
Currently open trials in the same condition.
- NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
- NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
- NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient · NA · recruiting
- NCT06879236 — Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease · recruiting
- NCT06888310 — Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease · NA · recruiting
Other Franciscus Gasthuis trials
Trials by the same sponsor.
- NCT06968442 — The Role of Obesity in Severe COVID-19 Pathophysiology · NA · recruiting
- NCT07155486 — IBD-SDM Telemonitoring Interview · completed
- NCT06179563 — TOD-IBD: Empowering Patients On-Demand · NA · enrolling by invitation
- NCT06084117 — High Flow Nasal Oxygen for Exacerbation COPD · NA · recruiting
- NCT06137261 — Screening Adults With Obesity to Reduce Heart Failure Events · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05499949 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Franciscus Gasthuis
- Last refreshed: 27 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05499949.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing